Fram-pfizer la jolla

T-800 P.009/018 F-984

PC25144A

15:28

Correction of Inventorship

2UEP224E3P4V3

Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV496345593US) in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

on this 24th day of February 2005.

Rachel Potash

+8386788233

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: SUZANNE BENEDICT, et al.

Serial No.: 10/754,171

Filed: January 9, 2004

For: TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1625

Examiner: AULAKH, CHARANJIT

CORRECTION OF INVENTORSHIP IN AN APPLICATION 37 CFR 1.48 (a)

Applicant requests to correct the Inventorship in the above-referenced application pursuant to 37 CFR 1.48(a). Inventors Yong Wang and JinJiang Zhu were inadvertently omitted from the Application. This error occurred without deceptive intent.

As requested in 37 CFR 1.48(a), Applicant attaches the following documents:

- A statement from each person being added as an inventor that the error in inventorship occurred without deceptive intention on his part;
- 2. An oath or declaration required by §1.67 (a)(2);
- 3. The processing fee set forth in §1.17(i); and
- 4. The written consent of the assignee set forth in §3.73(b).

If any other fees are due in connection with the filing of this response please charge all necessary fees to the deposit account 500329.

Respectfully submitted,

Date: 2/24/05

Reena R. Desai Agent For Applicants Registration No. 53,833

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department

10777 Science Center Drive San Diego, California 92121

Phone: (858) 526-4932 Fax: (858) 678-8233

15:30 Frem-pfizer la jolla Psb-24-05

> PC25144A Correction of Inventorship

+8586786233

Group Art Unit: 1625

Examiner: AULAKH, CHARANJIT

T-800 P.004/015 F-994

Certificate of Mailing (37 C.F.R. §1 10): I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV496345593US) in an envelope addressed to: Mail Stop: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 237d day of February 2005.

acl Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re the Application of: SUZANNE BENEDICT, et al .

Serial No.: 10/754,171

Filed: January 9, 2004

For: TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE **EFFICACY OF ANTI-NEOPLASTIC AGENTS**

AND RADIATION THERAPY

Commissioner For Patents P.O. Box 1450

Alexandria, VA 22313-1450

STATEMENT OF INVENTOR IN AN APPLICATION 37 CFR 1.48 (a)(2)

I, Yong Wang, was inadvertently omitted as an inventor in United States Patent Application No. 10/754,171, filed January 9, 2004. This error in inventorship occurred without deceptive intention on my part.

Respectfully submitted.

22/2005 Date:

Feb-24-38 18:83

Fram-pfizer la Jella

+8558786238

T-800 P.008/018 F-884

PC25144A Correction of Inventorship Certificate of Mailing (37 C.F.R. §1 10); I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV496345593US) in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

on this 23rd day of February 2005.

Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: SUZANNE BENEDICT, et al.

Serial No.: 10/754,171

Filed: January 9, 2004

For: TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS

AND RADIATION THERAPY

Group Art Unit: 1625

Examiner: AULAKH, CHARANJIT

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT OF INVENTOR IN AN APPLICATION 37 CFR 1.48 (a)(2)

I, Jinjiang Zhu, was inadvertently omitted as an inventor in United States Patent Application No. 10/754,171, filed January 9, 2004. This error in inventorship occurred without deceptive intention on my part.

Respectfully submitted,

Date: 2/22/05

Jinijano Zhu

PTC/SB/96 (09-04)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a varid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: Agouron Pharmaceuticals, Inc.	
Application No./Patent No.: 10/754,171 Filed/Issue Date: 01/09/2004	
Entitled: Tricyclic Compounds Protein Kinase Inhibitors For Anti-Neoplastic Agents And Radiation Therapy	Enhancing The Efficacy Of
Acouron Pharmaceuticals, Inc. , a <u>Conversion</u> (Name of Assignee) (Type of Assignee, e.g., conversiton)	n, partnership, university, government agency, etc.)
states that it is: 1. the assignee of the entire right, title, and interest; or	, sales of the sal
an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is	
in the patent application/patent identified above by virtue of either:	
A. An assignment from the inventor(s) of the patent application/patent identified a in the United States Patent and Trademark Office at Reel 014358 Francher of is attached. OR	ne <u>0202</u> , or for which a copy
B. A chain of title from the inventor(s), of the patent application/patent identified all below:	bove, to the current assignee as shown
From:	hereof is attached.
From:	
Reel, Frame, or for which a copy	Office at thereof is attached.
3. From:	
Additional documents in the chain of title are listed on a supplemental sheet.	
Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) Division in accordance with 37 CFR Part 3, if the assignment is to be recorde MPEP 302.08]	must be submitted to Assignment d in the records of the USPTO, <u>See</u>
The undersigned (whose title is supplied below) is authorized to act on behalf of the as	ssignee. February 16, 2005
Signature	Date
Bryan C, Ziellnski	<u>858-62</u> 2-8864
Printed or Typed Name	Telephone Number
Assistant Secretary	
Title	

This collection of Information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent end Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.